Soliqua

At a Glance
Therapeutic Area:
Type-2 Diabetes
Approved Applications:
Soliqua™ (formerly known as IGlarLixi or LixiLan, marketed as Suliqua™ in the European Union) is a once-daily, titratable, fixed-ratio combination of Sanofi’s long-acting basal insulin Lantus and Adlyxin. Soliqua is delivered in a pre-filled pen for once-daily dosing using Sanofi’s SoloSTAR™ technology, the most frequently used disposable insulin injection pen platform in the world.
Applications In Development:
N/A
Acquisition Date:
Undisclosed
Royalty Seller:
Undisclosed
Marketer:
 
 

Soliqua
"Sanofi continues to be a pioneer in developing diabetes therapies and in bringing forward new treatment options for the approximately 50 percent of patients whose blood sugar levels remain uncontrolled on daily basal insulin. Soliqua 100/33 is an alternate new approach that can help adults living with type-2 diabetes uncontrolled on basal insulin or lixisenatide to reach their treatment goal"

Elias Zerhouni, MD, President, Global R&D, Sanofi

Latest News

 
© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.